# Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion

> **NCT00913744** · PHASE2 · COMPLETED · sponsor: **ThromboGenics** · enrollment: 100 (actual)

## Conditions studied

- Exudative Age-Related Macular Degeneration
- Focal Vitreomacular Adhesion

## Interventions

- **DRUG:** Ocriplasmin
- **DRUG:** Sham injection

## Key facts

- **NCT ID:** NCT00913744
- **Lead sponsor:** ThromboGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913744, "Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00913744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*